Search
AZD-2836
go.drugbank.com/drugs/DB06031Investigational[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia
Chorionic Gonadotropin (Human)
go.drugbank.com/drugs/DB09126ApprovedInvestigationalVet approvedThe alpha sub-unit is essentially identical to the alpha sub units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit … As a drug product, chorionic gonadotropin is a highly purified pyrogen-free preparation obtained from the urine of pregnant females.
Methyclothiazide
go.drugbank.com/drugs/DB00232ApprovedWithdrawnA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411] … Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients.
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalAs a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Synonyms: 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide, N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINEMethyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnMethyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia. … Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.
Smallpox (Vaccinia) Vaccine, Live
go.drugbank.com/drugs/DB14711ApprovedInvestigationalThe New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. … [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499]
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalIt was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.